CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms
Jeffrey W Tyner, Thomas G.P. Bumm, Jutta Deininger et al. · Blood · 2010
Activating alleles of Janus kinase 2 (JAK2) such as JAK2(V617F) are central to the pathogenesis of myeloproliferative neoplasms (MPN), suggesting that small molecule inhibitors targeting JAK2 may be therapeutically useful. We have identified an aminopyrimidine derivative (CYT387), which inhibits JAK1, JAK2, and tyrosine kinase 2 (TYK2) at low nanomolar concentrations, with few additional targets. Between 0.5 and 1.5muM CYT387 caused growth suppression and apoptosis in JAK2-dependent hematopoietic cell lines, while nonhematopoietic cell lines were unaffected. In a murine MPN model, CYT387 normalized white cell counts, hematocrit, spleen size, and restored physiologic levels of inflammatory cytokines. Despite the hematologic responses and reduction of the JAK2(V617F) allele burden, JAK2(V617F) cells persisted and MPN recurred upon cessation of treatment, suggesting that JAK2 inhibitors may be unable to eliminate JAK2(V617F) cells, consistent with preliminary results from clinical trials of JAK2 inhibitors in myelofibrosis. While the clinical benefit of JAK2 inhibitors may be substantial, not the least due to reduction of inflammatory cytokines and symptomatic improvement, our data add to increasing evidence that kinase inhibitor monotherapy of malignant disease is not curative, suggesting a need for drug combinations to optimally target the malignant cells.
Cited by 240 works. doi:10.1182/blood-2009-05-223727 Open-access PDF
Authors
- Jeffrey W Tyner
- Thomas G.P. Bumm
- Jutta Deininger
- Lisa J. Wood
- Karl J. Aichberger
- Marc Loriaux
- Brian J. Druker
- Christopher J. Burns
- Emmanuelle Fantino
- Michael W. Deininger
References
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
- EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
- A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
- Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
- Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
- The development of imatinib as a therapeutic agent for chronic myeloid leukemia
- MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
- JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis
- European consensus on grading bone marrow fibrosis and assessment of cellularity.